Sanofi $SNY Stock Acquired by Pzena Investment Management LLC

Pzena Investment Management LLC increased its position in shares of Sanofi (NASDAQ:SNY) by 348.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,396 shares of the company’s stock after purchasing an additional 88,094 shares during the period. Pzena Investment Management LLC’s holdings in Sanofi were worth $4,675,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of SNY. Western Wealth Management LLC acquired a new stake in Sanofi in the first quarter valued at $29,000. Leonteq Securities AG lifted its holdings in Sanofi by 95.8% during the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after buying an additional 297 shares during the last quarter. Root Financial Partners LLC acquired a new position in shares of Sanofi during the 3rd quarter worth about $27,000. Whipplewood Advisors LLC boosted its position in shares of Sanofi by 2,086.1% during the 1st quarter. Whipplewood Advisors LLC now owns 787 shares of the company’s stock worth $38,000 after acquiring an additional 751 shares in the last quarter. Finally, Signature Equity Partners LLC increased its holdings in shares of Sanofi by 322.2% in the 3rd quarter. Signature Equity Partners LLC now owns 857 shares of the company’s stock valued at $35,000 after acquiring an additional 654 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on SNY shares. DZ Bank reissued a “buy” rating on shares of Sanofi in a research report on Friday, July 31st. Berenberg Bank restated a “buy” rating on shares of Sanofi in a research note on Monday, October 5th. Wall Street Zen downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. HSBC reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. Finally, UBS Group reissued a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Hold” and an average target price of $49.50.

Sanofi Price Performance

Shares of SNY opened at $46.91 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.12 and a quick ratio of 0.64. Sanofi has a 1-year low of $39.07 and a 1-year high of $52.68. The stock has a market cap of $113.73 billion, a PE ratio of 23.22, a price-to-earnings-growth ratio of 1.30 and a beta of 0.31. The firm has a fifty day moving average price of $42.25 and a 200 day moving average price of $44.33.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.56 by $0.48. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The company had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.30 billion. During the same quarter last year, the company posted $2.91 earnings per share. The business’s quarterly revenue was up 16.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sanofi will post 5.07 EPS for the current year.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.